Stock Trading

CombinatoRx, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and outlicensing synergistic combination pharmaceuticals. It develops novel therapeutics with multi-target mechanisms of action that are built from combinations of drugs that utilize novel biology to treat various conditions, including immuno-inflammatory diseases, cancer, metabolic diseases, inherited diseases, and other diseases. The company’s products include Synavive, a novel dissociated glucocorticoid product candidate to enhance the anti-inflammatory benefits of glucocorticoids, which completed phase II in rheumatoid arthritis, knee osteoarthritis, hand osteoarthritis, and biomarker study; CRx-401, an anti-diabetic agent, which is in phase IIa clinical study; and CRx-191, a topical synergistic combination drug candidate that has completed phase IIa clinical trials for psoriasis. Its products also include CRx-197, a novel topical anti-inflammatory product candidate that completed phase IIa clinical trials for the treatment of psoriasis, atopic dermatitis, and other inflammatory dermatoses; and CRx-170, an oral synergistic combination drug candidate, which completed phase IIa clinical trial for the potential treatment of chronic pain conditions. The company has a collaboration and licensing agreement with Clinical Data Inc. to develop an adenosine A2A agonist compound in a combination therapy for the treatment of multiple myeloma, and other B-cell cancers. CombinatoRx, Incorporated also has collaborations with Angiotech Pharmaceuticals, Inc.; Fovea Pharmaceuticals SA; Cystic Fibrosis Foundation Therapeutics Incorporated; CHDI, Inc.; Charley’s Fund and the Nash Avery Foundation; National Institutes of Allergy and Infectious Diseases; HenKan Pharmaceutical Company; Spinal Muscular Atrophy Foundation; Sirtris Pharmaceuticals, Inc.; and Novartis AG. The company was founded in 2000 and is based in Cambridge, Massachusetts

NEW YORK (AP) -- The Food and Drug Administration approved the sale of CombinatoRx Inc.'s extended-release pain drug Exalgo, the company said Tuesday.

Exalgo is intended to treat moderate to severe pain in patients who require treatment with opioid painkillers for an extended period of time. CombinatoRx developed the drug, and Covidien PLC is responsible for marketing, sales, and regulatory filings after approval.

Covidien will pay CombinatoRx $40 million as a result of the FDA ruling, and CombinatoRx will also get royalty payments on sales of Exalgo.

Shares of Cambridge, Mass.-based CombinatoRx jumped 46 cents, or 41.4 percent, to $1.57 in premarket trading. Shares of Covidien, which is based in Ireland, were unchanged at $49.53.

CRXX Up very nicely on approval news, This is a stock that we have been talking about for the last few days in the chat room, Congrats to all who got in. Please join us in our live stock traders chat room and share your thoughts on CRXX at the link below.

http://www.stockplaysonline.com/visichat/